返回
Theranostic Trigger-Responsive Carbon Monoxide-Generating Microbubbles
DOI:10.1002/smll.202200924.png)
摘要
En 中文
Carbon monoxide (CO) is a gaseous signaling molecule that modulates inflammation, cell survival, and recovery after myocardial infarction. However, handling and dosing of CO as a compressed gas are difficult. Here, light-triggerable and magnetic resonance imaging (MRI)-detectable CO release from dimanganese decacarbonyl (CORM-1) are demonstrated, and the development of CORM-1-loaded polymeric microbubbles (COMB) is described as an ultrasound (US)- and MRI-imageable drug delivery platform for triggerable and targeted CO therapy. COMB are synthesized via a straightforward one-step loading protocol, present a narrow size distribution peaking at 2 mu m, and show excellent performance as a CORM-1 carrier and US contrast agent. Light irradiation of COMB induces local production and release of CO, as well as enhanced longitudinal and transversal relaxation rates, enabling MRI monitoring of CO delivery. Proof-of-concept studies for COMB-enabled light-triggered CO release show saturation of hemoglobin with CO in human blood, anti-inflammatory differentiation of macrophages, reduction of hypoxia-induced reactive oxygen species (ROS) production, and inhibition of ischemia-induced apoptosis in endothelial cells and cardiomyocytes. These findings indicate that CO-generating MB are interesting theranostic tools for attenuating hypoxia-associated and ROS-mediated cell and tissue damage in cardiovascular disease.
Keyword:
carbon monoxide therapy
cardiovascular disease
microbubbles
poly-n-butyl-cyanoacrylate (PBCA)
ultrasound
期刊
IF:
12.1
论文数:
3.0W
被引数:
16.4W
机构
引用论文
Within‐host viral evolution in a heterogeneous environment: insights into the HIV co‐receptor switch
Cardiac monocytes and macrophages after myocardial infarction心肌梗死后的心肌单核细胞和巨噬细胞
CARDIOVASCULAR RESEARCH
IF13.3
Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury
NATURE MEDICINE
IF50
Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis
NATURE MEDICINE
IF50
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis低剂量吸入一氧化碳治疗特发性肺纤维化的II期临床试验
CHEST
IF8.6
Balancing stealth and echogenic properties in an ultrasound contrast agent with drug delivery potential
BIOMATERIALS
IF12.9
Novel lead structures and activation mechanisms for CO-releasing molecules (CORMs)CO释放分子 (CORMs) 的新型先导结构和激活机制

